"GLP-1 microdosing" is a marketing term. It is not a standard clinical dose category.
The term can describe several different practices. One provider can mean a slow start. Another can mean a dose below the approved starting dose. A third can mean longer gaps between injections. These practices do not have the same evidence.
This article explains the difference between approved treatment, individual clinical adjustment, and a commercial microdose program. It does not give dose instructions.
There is no standard definition
FDA-approved GLP-1 products have specific prescribing information. The current Wegovy prescribing information gives defined starting, escalation, and maintenance schedules for GLP-1S. The Zepbound prescribing information does the same for GLP-2T.
A prescriber can adjust treatment when a patient has side effects or another clinical need. This is individualized care. It does not create evidence for every program that uses the word "microdose."
Before a person compares programs, the provider must answer three questions:
- What medicine is prescribed?
- Is it an FDA-approved product or a compounded drug?
- What clinical rule determines when the treatment changes?
Without these answers, the word "microdose" gives little useful information.
What the major trials tested
The large weight-loss trials did not test commercial microdose programs.
The STEP 1 trial enrolled 1,961 adults. It tested once-weekly GLP-1S with a defined escalation to the studied maintenance treatment. The average weight change at 68 weeks was 14.9% with GLP-1S and 2.4% with placebo.
The SURMOUNT-1 trial enrolled 2,539 adults. It tested defined GLP-2T treatment groups. Average weight reduction at 72 weeks ranged from 15.0% to 20.9%, compared with 3.1% with placebo.
These results show that GLP-1S and GLP-2T can produce substantial weight loss under studied conditions. They do not show that a much smaller or less frequent dose gives the same result.
What is known about staying at a lower dose?
Some patients respond before they reach a maintenance dose. Some patients need a slower change because of adverse effects. A licensed prescriber can make an individual decision.
This clinical fact is often used to support a broader claim: that very small doses give most of the benefit with few adverse effects. Large controlled trials have not established that claim.
The two statements are different:
- Supported: clinicians can individualize treatment within medical practice.
- Not established: a commercial microdose schedule gives durable weight loss or long-term health benefits comparable with approved schedules.
Compounded products add another question
Many microdose programs use compounded GLP-1S or GLP-2T. Compounded drugs are not FDA-approved generic drugs.
FDA's current unapproved GLP-1 safety page states that compounded products do not receive FDA review for safety, effectiveness, or quality before marketing. As of May 31, 2026, FDA had received 990 adverse-event reports linked to compounded GLP-1S and more than 730 linked to compounded GLP-2T. A report does not prove that the product caused the event, and FDA says these events are probably underreported.
FDA has also reported measurement errors with compounded GLP-1S. Some people received five to 20 times the intended amount because concentrations, syringes, milligrams, milliliters, and "units" caused confusion.
Small intended amounts do not remove measurement risk. In some cases, a small volume can make accurate measurement more difficult.
Does microdosing reduce adverse effects?
Gastrointestinal adverse effects are common with GLP-1 treatment. Slow escalation is already part of approved schedules because tolerability matters.
A smaller amount can reduce exposure, but three uncertainties remain:
- It may also reduce effectiveness.
- The best long-term amount is not known for a commercial microdose schedule.
- The actual concentration and measurement process can differ for a compounded vial.
A provider must not promise that a patient will have no adverse effects. In March 2026, FDA announced warning letters to 30 telehealth companies for false or misleading compounded-GLP-1 claims. The agency objected to claims that implied compounded products were the same as FDA-approved drugs.
What does a microdose program cost?
The price has two parts: the first payment and the continuing cost.
In July 2026, Noom's official microdose page advertised a $79 initial payment and a continuing price of $179 per month. The page states that medication, ongoing care, and program access are included if a clinician prescribes treatment.
PeptidePrices lists Telos RX with microdosed GLP-2T from $69 for the first month. This is an introductory price, not a verified continuing monthly price.
Prices can change without notice. Compare these items before payment:
| Cost item | Question to ask |
|---|---|
| Continuing subscription | What will the second and third months cost? |
| Medication | Is it included, and what product can the clinician prescribe? |
| Pharmacy and shipping | Which licensed pharmacy dispenses it, and is cold shipping included? |
| Supplies and laboratory tests | Are needles, visits, and required tests included? |
| Cancellation | Is there a minimum term or prepaid commitment? |
The lowest first-month number is not the total treatment cost.
Provider checks
Use these checks for any GLP-1 microdose offer:
- A licensed clinician reviews the patient's history before prescribing.
- The program names the medicine and states whether it is compounded.
- The dispensing pharmacy is licensed for the patient's state.
- The instructions use clear units and match the supplied syringe or device.
- The provider gives a clear route for adverse-effect questions and urgent care.
Do not use a product sold as a research chemical for personal treatment.
Bottom line
GLP-1 microdosing is popular, but it is not a defined or FDA-approved treatment schedule. The best evidence for GLP-1S and GLP-2T comes from large trials that used defined schedules. Those trials cannot prove the claims of a commercial microdose program.
A lower dose can be a valid individual decision under medical care. It is not proof that all low-dose programs are effective, safer, or lower in total cost.
Related pages: compare weight-loss telehealth providers, review the GLP-1S evidence, and review the GLP-2T evidence.
Sources
- Wegovy prescribing information
- Zepbound prescribing information
- STEP 1 GLP-1S trial
- SURMOUNT-1 GLP-2T trial
- FDA concerns with unapproved GLP-1 products
- FDA alert about compounded-GLP-1S dose errors
- FDA telehealth warning-letter announcement
- Noom Microdose GLP-1Rx program and price
Educational information only. This article does not recommend a medicine or dose. A licensed clinician must make treatment decisions for an individual patient.